Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Oral, Dose Escalation Phase 1 Study to Evaluate the Safety and Tolerance of MF 101 as Well as the Pharmacokinetics of Its Key Active Components in Healthy Post-Menopausal Women.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs MF 101 (Primary)
- Indications Vasomotor symptoms
- Focus Adverse reactions
- 15 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Jun 2007 New trial record.